0001479290-22-000063.txt : 20220506
0001479290-22-000063.hdr.sgml : 20220506
20220506181936
ACCESSION NUMBER: 0001479290-22-000063
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220504
FILED AS OF DATE: 20220506
DATE AS OF CHANGE: 20220506
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nolet Chris
CENTRAL INDEX KEY: 0001782814
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 22902713
MAIL ADDRESS:
STREET 1: C/O REVANCE THERAPEUTICS, INC.
STREET 2: 7555 GATEWAY BOULEVARD
CITY: NEWARK
STATE: CA
ZIP: 94560
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wf-form4_165187555569277.xml
FORM 4
X0306
4
2022-05-04
0
0001479290
Revance Therapeutics, Inc.
RVNC
0001782814
Nolet Chris
C/O REVANCE THERAPEUTICS, INC
1222 DEMONBREUN STREET, SUITE 1001
NASHVILLE
TN
37203
1
0
0
0
Common Stock
2022-05-04
4
A
0
6059
0
A
25072
D
Stock Option (Right to buy)
18.12
2022-05-04
4
A
0
11343
0
A
2032-05-03
Common Stock
11343.0
11343
D
Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.
/s/ Dwight Moxie, Attorney-in-Fact
2022-05-06